Telix Pharmaceuticals Limited ADR TLX

$10.55 -0.17 (-1.59%)

Valuation

Market cap: 3,643,642,000
Revenue TTM: $803,790,000
Net income TTM: $-7,130,000
PE ratio: 0.00
Forward PE: 105.48
Profit margin: -0.89%
Debt to equity: 1.06

Trading

Volume: 299,600
Avg volume: 275,536
Day's range: $10.45 – $10.64
Shares out: 339,892,000
Stochastic %K: 6%
Beta: -0.17
Analysts: Strong Sell
Price target: $20.80

Price

Company profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9093 3855
Website: https://telixpharma.com
Address: 55 Flemington Road, Level 4, North Melbourne, Australia

Latest news

No headlines yet.

Stocktwits

RadioIsotope25 Oct 2, 12:48 PM

$TLX https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-ex99_1.htm

0 replies

Quantumup Sep 30, 6:57 PM

H.C. Wainwright on $TLX (Buy; PT $20) said: We view the FDA's decision to grant Fast Track designation to BiPASS as incrementally positive. $LNTH $NVS GEHC MYGN OPK MDXH Here's what H.C. Wainwright went on to say in its note to investors: https://x.com/Quantumup1/status/2105371184313336167?s=20

0 replies

Mani86 Sep 30, 1:31 PM

$TLX https://www.marketindex.com.au/asx/tlx/announcements/fda-fast-track-for-bipass-pre-biopsy-prostate-imaging-3A702845

0 replies

Invescent Sep 30, 6:41 AM

NEWS AFTER MARKET CLOSE $VNDA — 6:45 PM ET Positive Phase 3 results. Trial met its primary endpoint. FDA submission planned. $DBVT — 6:28 PM ET Submitted BLA to the FDA for VIASKIN Peanut Patch. Priority Review requested. $DYN — 4:05 PM ET New one year Phase 1/2 clinical data released. $CAPR — New 24 month deramiocel data. Shares moved roughly 20% after hours. $TLX — FDA Fast Track designation for its BiPASS prostate cancer imaging program. Stocks to watch heading into premarket. $VNDA $DBVT $DYN $CAPR $TLX

0 replies

RadioIsotope25 Sep 28, 1:41 PM

$CATX If ESMO repeats roughly 43% ORR in the broader Cohort 2 population, with the same clean renal/marrow safety and responses continuing to deepen, I’d put a plausible whole-company buyout range at $1.0–$1.6 billion—roughly $8.75–$14 per CATX share on ~114 million shares. Why that range: CATX already has about $237M cash plus a real manufacturing network under build, so a buyer is not just paying for a Phase 1/2 dataset. The first 23 Cohort 2 patients showed 10 responses / 43%, with 50% in the all-SSTR2-expressing subgroup, and the reported safety profile has been notably clean for an alpha program. Repeating it de-risks the result; it does not yet prove registrational durability, $DRTS $TLX $IOVA

1 replies

Merlintrader Sep 26, 9:25 AM

Prostate cancer: where can four approaches improve care? $BNTX, $CADL, $JANX, $TLX https://www.merlintrader.com/prostate-cancer-four-approaches-bntx-cadl-janx-tlx/

0 replies

Merlintrader Sep 23, 7:12 PM

Telix ($TLX): Proposed ITM Acquisition, FDA Approves Pixclara for Glioma Imaging Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/telix-pharmaceuticals-tlx-stock-hub/

0 replies

JFais Sep 23, 12:45 PM

$TLX (L) Shared a few nuggets from R&D Day in Chat- here's one: TLX597 = their next-generation small molecule for PSMA Imparts half the dose to the kidneys and 1/3rd to the salivary glands while delivering 2x to the tumor target vs Gen1 $NVS Pluvicto Finished enrolling in June and topline readout is expected around/at ASCO GU in early 2027 (eagerly anticipated) Below: Encouraging case study with very fragile patient, 99% PSA response at Week 20

0 replies